Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 176
Filtrar
Más filtros

Intervalo de año de publicación
1.
Br J Clin Pharmacol ; 90(5): 1333-1343, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38403473

RESUMEN

AIMS: The purpose of this work was to assess failures in the advanced prescription of parenteral anticancer agents in an adult day oncology care unit with more than 100 patients per day. METHODS: An a priori descriptive analysis was carried out by using the risk matrix approach. After defining the scope in a multidisciplinary meeting, we determined at each step the failure modes (FMs), their effects (E) and their associated causes (C). A severity score (S) was assigned to all effects and a probability of occurrence (O) to all causes. These S and O indicators, were used to obtain a criticality index (CI) matrix. We assessed the risk control (RC) of each failure in order to define a residual criticality index (rCI) matrix. RESULTS: During risk analysis, 14 FMs were detected, and 61 scenarios were identified considering all possible effects and causes. Nine situations (15%) were highlighted with the maximum CI, 18 (30%) with a medium CI, and 34 (55%) with a negligible CI. Nevertheless, among all these critical situations, only three (5%) had an rCI to process (i.e., missed dose adjustment, multiple prescriptions and abnormal biology data); the others required monitoring only. Clinicians' and pharmacists' knowledge of these critical situations enables them to manage the associated risks. CONCLUSIONS: Advanced prescription of injectable anticancer drugs appears to be a safe practice for patients when combined with risk management. The major risks identified concerned missed dose adjustment, prescription duplication and lack of consideration for abnormal biology data.


Asunto(s)
Antineoplásicos , Humanos , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Medición de Riesgo , Errores de Medicación/prevención & control , Errores de Medicación/estadística & datos numéricos , Neoplasias/tratamiento farmacológico , Prescripciones de Medicamentos/estadística & datos numéricos , Prescripciones de Medicamentos/normas , Inyecciones , Instituciones Oncológicas/estadística & datos numéricos , Instituciones Oncológicas/organización & administración , Análisis de Modo y Efecto de Fallas en la Atención de la Salud , Adulto
2.
J Drugs Dermatol ; 20(4): 366-372, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33852242

RESUMEN

BACKGROUND: Impetigo is a contagious bacterial infection that affects the superficial skin layers. Increasing worldwide antimicrobial resistance (AMR) to existing topical agents commonly prescribed to treat impetigo is central to treatment failure. The Worldwide Health Organization developed a global action plan on AMR, but omitted information about AMR stewardship programs for topical antibiotics. OBJECTIVES: The review aims to provide information to clinicians and stakeholders regarding AMR and antimicrobial stewardship on topical antimicrobial drugs for impetigo treatment. METHODS: The literature searches reviewed the status of AMR to current topical antibiotics in impetigo, current therapeutic behavior, and concordance with antimicrobial stewardship principles. Two international panels convened to discuss the output of the searches, and the results of the panel discussions were used in the development of the manuscript. RESULTS: The literature search included clinical trials, research studies, clinical guidelines, consensus papers, and reviews (if they provided original data), published between January 2008 and May 2019. The articles were selected based on clinical relevancy of impetigo management, clinical efficacy, and safety of the treatment and antimicrobial resistance. The searches resulted in one-hundred and ninety-eight articles. After applying the eligibility criteria, nineteen articles met inclusion criteria and were considered in the present review. CONCLUSIONS: While published antimicrobial stewardship guidelines have focused on systemic antibiotics, few studies have attempted to evaluate topical antibiotic prescribing practices for impetigo treatment. Many of the topical impetigo treatments currently in use have developed resistance. The appropriate use of topical ozenoxacin can help eradicate impetigo while minimizing AMR.J Drugs Dermatol. 20(4):366-372. doi:10.36849/JDD.5795.


Asunto(s)
Antibacterianos/farmacología , Programas de Optimización del Uso de los Antimicrobianos/normas , Impétigo/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Administración Cutánea , Aminopiridinas/farmacología , Aminopiridinas/normas , Aminopiridinas/uso terapéutico , Antibacterianos/normas , Antibacterianos/uso terapéutico , Prescripciones de Medicamentos/normas , Farmacorresistencia Bacteriana , Humanos , Pruebas de Sensibilidad Microbiana , Guías de Práctica Clínica como Asunto , Quinolonas/farmacología , Quinolonas/normas , Quinolonas/uso terapéutico , Staphylococcus aureus/aislamiento & purificación , Resultado del Tratamiento
3.
London; NICE; rev; Mar. 22, 2021. 28 p. tab.
Monografía en Inglés | BIGG | ID: biblio-1357593

RESUMEN

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.


Asunto(s)
Humanos , Prescripciones de Medicamentos/normas , Cannabinoides/uso terapéutico , Marihuana Medicinal , Epilepsia , Dolor Crónico , Espasticidad Muscular , Náusea
4.
Am J Clin Dermatol ; 22(2): 193-204, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32918267

RESUMEN

Oral antibiotics are integral for treating inflammatory acne based on what is understood about the pathogenesis as well as the role of Cutibacterium acnes. However, rising concerns of antibiotic resistance and the perception of "antibiotic phobia" create potential limitations on their integration in an acne treatment regimen. When prescribing oral antibiotics, dermatologists need to consider dosage, duration, and frequency, and to avoid their use as monotherapy. These considerations are important, along with the use of newer strategies and compounds, to reduce adverse-event profiles, antibiotic resistance, and to optimize outcomes. Aside from concomitant medications, allergies, and disease severity, costs and patient demographics can influence variability in prescribing plans. There are multiple published guidelines and consensus statements for the USA and Europe to promote safe antibiotic use by dermatologists. However, there is a lack of head-to-head studies and evidence for comparative superiority of any individual antibiotic, as well as any evidence to support the use of agents other than tetracyclines. Although oral antibiotics are one of the main options for moderate to severe acne, non-antibiotic therapy such as isotretinoin and hormonal therapies should be considered. As newer therapies and more outcomes data emerge, so will improved management of antibiotic therapy to foster patient safety.


Asunto(s)
Acné Vulgar/tratamiento farmacológico , Antibacterianos/uso terapéutico , Propionibacterium acnes/efectos de los fármacos , Acné Vulgar/microbiología , Administración Oral , Antibacterianos/farmacología , Anticonceptivos Orales/uso terapéutico , Dermatología/métodos , Dermatología/normas , Prescripciones de Medicamentos/normas , Farmacorresistencia Bacteriana , Quimioterapia Combinada/métodos , Humanos , Isotretinoína/uso terapéutico , Pruebas de Sensibilidad Microbiana/normas , Guías de Práctica Clínica como Asunto , Propionibacterium acnes/aislamiento & purificación , Espironolactona/uso terapéutico , Resultado del Tratamiento
5.
Braz. J. Pharm. Sci. (Online) ; 57: e181060, 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1350238

RESUMEN

The purpose of this study is to describe the frequency of potential drug prescribing omissions (PPOs) for elderly patients at the time of hospital discharge and to compare the frequency PPOs among different medical specialities. This cross-sectional study examined data from elderly patients when they were admitted for >24 h to a northeastern Brazil teaching hospital during June-December 2016. Were included in the study 227 patients, of whom 36.9% had at least one PPO. The highest number of PPOs was identified among those with at least 5 prescribed drugs. In total, 153 PPOs were identified at hospital discharge. In most cases (78.4%), patients were not evaluated by the specialist physician.The most commonly identified PPOs on discharge were: the omission of statin therapy in cases of diabetes mellitus plus one or more cardiovascular-associated factor; calcium and vitamin D supplements in patients with known osteoporosis; and angiotensin converting enzyme inhibitors in cases of chronic heart failure. The results of this study suggest that the frequency of prescribing omissions PPOs during patient discharge was high. This can be avoided by the careful evaluation by prescribers with experience in certain specialties where several prescribed omissions would be common.


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Alta del Paciente/normas , Alta del Paciente/estadística & datos numéricos , Médicos , Prescripciones de Medicamentos/normas , Mal Uso de Medicamentos de Venta con Receta/estadística & datos numéricos , Lista de Medicamentos Potencialmente Inapropiados/clasificación , Servicios de Salud para Ancianos/provisión & distribución , Servicios de Salud para Ancianos/ética , Hospitales , Estudios Transversales , Diabetes Mellitus/tratamiento farmacológico , Seguridad del Paciente/normas , Geriatría/clasificación
6.
Epilepsy Behav ; 113: 107575, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33242770

RESUMEN

AIMS: To enumerate and classify errors in physicians' orders of antiseizure medications (ASMs) to people with epilepsy presenting to neurology clinic. METHODS: This cross-sectional study was conducted in the neurology clinic of a teaching hospital catering to a predominantly rural population. People in whom a diagnosis of epilepsy was confirmed and who presented for the first time with a prior prescription for antiseizure medication/s were included. Their immediate previous prescriptions were assessed for errors, enumerated and classified according to WHO guidelines for prescription writing. RESULTS: Hundred prescriptions of 334 patients screened were analyzed. The number of ASMs prescribed to a participant was 2 ±â€¯0.6 (mean ±â€¯SD). We identified a mean of 5 ±â€¯4 (median: 3; range: 1-7) errors in each order. These included superscription errors, e.g., missing information on seizure control and frequency (n = 90, 90%), generic name (n = 62, 62%), patient identifiers (n = 57, 57%), prescribers' identifiers (n = 29, 29%) and diagnosis or indication for prescribing the medication/s (n = 55, 55%). The most common inscription and subscription errors were dosing errors (22%) and pharmaceutical form errors (20%) followed by omission (13%), duplication (13%), substitution (12%), commission (9%) and frequency errors (8%). Errors were more common among prescriptions provided by primary-care and Ayurvedic, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH) physicians compared to specialists (P < 0.05). CONCLUSIONS: Errors are common among medication orders provided by non-specialist and specialist physicians. Primary care and AYUSH are more liable to make errors underscoring the need to educate them in basic epilepsy treatment.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Errores de Medicación , Adolescente , Adulto , Niño , Preescolar , Estudios Transversales , Prescripciones de Medicamentos/normas , Femenino , Hospitales de Enseñanza , Humanos , India , Lactante , Masculino , Persona de Mediana Edad , Fisiatras , Médicos , Atención Primaria de Salud , Población Rural , Adulto Joven
7.
BMC Pregnancy Childbirth ; 20(1): 624, 2020 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-33059613

RESUMEN

BACKGROUND: A vigilant prescription of drugs during pregnancy can potentially safeguard the growing fetus from the deleterious effect of the drug while attempting to manage the mother's health problems. There is a paucity of information about the drug utilization pattern in the area of investigation. Hence, this study was implemented to investigate the pattern of drug utilization and its associated factors among pregnant women in Adigrat general hospital, Northern Ethiopia. METHODS: An institution-based cross-sectional study was conducted among randomly selected 314 pregnant women who attended obstetrics-gynecology and antenatal care units of the hospital. Relevant data were retrieved from the pregnant women's medical records and registration logbook. The drugs prescribed were categorized based on the United States Food and Drug Administration (US-FDA) fetal harm classification system. Data analysis was done using SPSS version 20 statistical software. Multivariate logistic regression was employed to analyze the association of the explanatory variables with the medication use, and p < 0.05 was declared statistically significant. RESULTS: The overall prescribed drug use in this study was found to be 87.7%. A considerable percentage of the study participants (41.4%) were prescribed with supplemental drugs (iron folate being the most prescribed drug) followed by antibiotics (23.4%) and analgesics (9.2%). According to the US-FDA drug's risk classification, 42.5, 37, 13, and 7% of the drugs prescribed were from categories A, B, C, and D or X respectively. Prescribed drug use was more likely among pregnant women who completed primary [AOR = 5.34, 95% CI (1.53-18.6)] and secondary education [AOR = 4.1, 95% CI (1.16-14)], who had a history of chronic illness [AOR = 7.9, 95% CI (3.14-19.94)] and among multigravida women [AOR = 2.9, 95% CI (1.57 5.45)]. CONCLUSIONS: The finding of this study revealed that a substantial proportion of pregnant women received drugs with potential harm to the mother and fetus. Reasonably, notifying health practitioners to rely on up-to-date treatment guidelines strictly is highly demanded. Moreover, counseling and educating pregnant women on the safe and appropriate use of medications during pregnancy are crucial to mitigate the burden that the mother and the growing fetus could face.


Asunto(s)
Utilización de Medicamentos/estadística & datos numéricos , Hospitales Generales/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Complicaciones del Embarazo/tratamiento farmacológico , Medicamentos bajo Prescripción/uso terapéutico , Adolescente , Adulto , Estudios Transversales , Prescripciones de Medicamentos/normas , Prescripciones de Medicamentos/estadística & datos numéricos , Utilización de Medicamentos/normas , Etiopía , Femenino , Adhesión a Directriz/estadística & datos numéricos , Hospitales Generales/normas , Humanos , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/normas , Embarazo , Atención Prenatal/estadística & datos numéricos , Estudios Retrospectivos , Adulto Joven
8.
Medicine (Baltimore) ; 99(36): e22023, 2020 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-32899056

RESUMEN

BACKGROUND: Traditional Chinese medicine (TCM) or combined with western medicine in the treatment of pediatric adenoidal hypertrophy has been widely used in clinical practice, but the overall efficacy and safety is still unclear. This paper aims to evaluate the efficacy and safety analysis of TCM or combined with western medicine for pediatric adenoidal hypertrophy. METHODS: PubMed, EMbase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang, the Chongqing VIP Chinese Science and Technology Periodical Database, and China biomedical literature database (CBM) were searched for randomized controlled trials of TCM or combined with western medicine for pediatric adenoidal hypertrophy from the date of establishment to July 2020, and Baidu Scholar, Google Scholar, International Clinical Trials Registry Platform (ICTRP), and Chinese Clinical Trials Registry (ChiCTR) were searched for unpublished grey literature. Two researchers independently applied RevMan 5.3 software for data extraction and risk assessment of bias. RESULTS: The effectiveness and safety of TCM or combined with western medicine for pediatric adenoidal hypertrophy is evaluated by means of the Adenoid (A) /(Nasopharyngeal (N) ratio, clinical efficacy, integral score of TCM syndromes, clinical single symptom score, disease specific quality of life for children with obstructive sleep apnea 18 items survey (OSA-18), Interleukin 4 (IL-4) and adverse reaction incidence. CONCLUSION: This study will provide theoretical support for the clinical application of TCM or combined with western medicine for pediatric adenoidal hypertrophy. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/J76AG.


Asunto(s)
Tonsila Faríngea/patología , Medicamentos Herbarios Chinos/uso terapéutico , Hipertrofia/terapia , Medicina Tradicional China/métodos , Niño , China/epidemiología , Terapia Combinada , Prescripciones de Medicamentos/normas , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Interleucina-4/sangre , Masculino , Calidad de Vida , Seguridad , Apnea Obstructiva del Sueño/epidemiología , Apnea Obstructiva del Sueño/psicología , Resultado del Tratamiento , Metaanálisis como Asunto
9.
Medicine (Baltimore) ; 99(36): e22039, 2020 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-32899062

RESUMEN

BACKGROUND: Clinical studies found that the combination of traditional Chinese herbal formula, and western medicine therapy are better in shrinking fibroids and improve other symptoms. This study aims to systematically evaluate the efficacy and safety traditional Chinese herbal formula combined with western medicine in the treatment of uterine fibroids. METHODS: Randomized controlled trials of traditional Chinese herbal formula combined with western medicine for uterine fibroids patients will be searched in PubMed, Medline, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chongqing VIP Chinese Science and Technology Periodical Database, Chinese Biological and Medical database (CMB), and Wanfang database from inception to August 2020. Two researchers will perform data extraction and risk of bias assessment independently. Statistical analysis will be conducted in RevMan 5.3. RESULTS: This study will summarize the present evidence by exploring the efficacy and safety of traditional Chinese herbal formula combined with western medicine in the treatment of uterine fibroids CONCLUSIONS:: The findings of the study will help to determine potential benefits of traditional Chinese herbal formula combined with western medicine in the treatment of uterine fibroids. ETHICS AND DISSEMINATION: The private information from individuals will not be published. This systematic review also will not involve endangering participant rights. Ethical approval is not required. The results may be published in a peer-reviewed journal or disseminated in relevant conferences. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/XUA8V.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Leiomioma/tratamiento farmacológico , Medicina Tradicional China/métodos , China/epidemiología , Terapia Combinada , Prescripciones de Medicamentos/normas , Femenino , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Seguridad , Resultado del Tratamiento , Metaanálisis como Asunto
10.
Contemp Nurse ; 56(4): 388-399, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32814514

RESUMEN

Aims: This study aimed to investigate the experiences of registered prescribers and their perceptions of the enablers and barriers to registered prescribing and the value of this fledgling role. Background: The role of prescribing has been extended to registered nurses in New Zealand. By adding the designated prescribing role to a nurse's role, their scope of practice expands and nurses are able to provide patients with holistic care while achieving greater independence and role satisfaction. Yet new nurse prescribers can experience anxiety and fear when confronted with the reality of the responsibility of prescribing. Methods: Sixteen semi-structured interviews were conducted with registered nurse prescribers across New Zealand. Data were analysed using a general inductive approach and thematic analysis utilised to identify themes and sub-themes. Results: Sixteen registered nurse prescribers participated in the study. Three main themes emerged with sub-themes: ability to expand practice, improving access to care, and importance of working in a collaborative team. Participants explained how they enjoyed the challenge and responsibility of the new prescribing role yet were frustrated with the realities of the restrictions of what they could actually prescribe and in some cases lack of role recognition. Registered nurse prescribing also improved access to care as nurses felt they provided more comprehensive care, resulting in reduced wait times, better continuity of care and a reduction in patient costs. The participants highlighted the importance of working in a collaborative team and believed their ability to prescribe maximised clinician time, however cautioned the need for on-going clinical mentorship and a prepared and supportive work environment. Conclusions: The addition of registered nurse prescribing provides a number of advantages to individual nurses in terms of career development and job satisfaction, and to patients and the health care system. The benefits to health care consumers and the health care system align directly to health care priorities of improving equity and access to care. Impact statement: Registered nurse prescribers perceive a number of advantages to the addition of prescribing to their own practice and benefits to patients and the health care system by enabling more accessible and cost-effective care.


Asunto(s)
Prescripciones de Medicamentos/normas , Enfermeras Practicantes/psicología , Enfermeras Practicantes/normas , Rol de la Enfermera/psicología , Enfermeras y Enfermeros/psicología , Enfermeras y Enfermeros/normas , Pautas de la Práctica en Enfermería/estadística & datos numéricos , Adulto , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nueva Zelanda , Enfermeras Practicantes/estadística & datos numéricos , Enfermeras y Enfermeros/estadística & datos numéricos , Investigación Cualitativa
11.
Am J Clin Dermatol ; 21(3): 411-419, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32107726

RESUMEN

Acne vulgaris is the most common skin disease treated by dermatologists. It can be severe and result in permanent scars. Isotretinoin is the most effective treatment for acne and has the potential for long-term clearance. Prescribing and monitoring protocols can vary widely among prescribers. Recent studies, reports, and consensus statements help shed light on optimizing the use of isotretinoin for acne. A recent literature review is summarized in this article to help the practitioner optimize isotretinoin use for acne. The article outlines the advantages and disadvantages of standard, high-dose, and low-dose isotretinoin regimens; discusses the current status of controversies surrounding isotretinoin (including depression/suicide, pregnancy, and inflammatory bowel disease); reviews monitoring recommendations and treatment for hypertriglyceridemia and elevated transaminase levels; and discusses common adverse effects seen with isotretinoin, along with their treatment and prevention.


Asunto(s)
Acné Vulgar/tratamiento farmacológico , Prescripciones de Medicamentos/normas , Isotretinoína/administración & dosificación , Guías de Práctica Clínica como Asunto , Teratógenos/toxicidad , Anomalías Inducidas por Medicamentos/etiología , Anomalías Inducidas por Medicamentos/prevención & control , Acné Vulgar/psicología , Ansiedad/inducido químicamente , Ansiedad/prevención & control , Ansiedad/psicología , Anticoncepción/normas , Depresión/inducido químicamente , Depresión/prevención & control , Depresión/psicología , Relación Dosis-Respuesta a Droga , Monitoreo de Drogas/normas , Femenino , Humanos , Enfermedades Inflamatorias del Intestino/inducido químicamente , Enfermedades Inflamatorias del Intestino/prevención & control , Isotretinoína/efectos adversos , Isotretinoína/toxicidad , Cooperación del Paciente , Educación del Paciente como Asunto , Embarazo , Suicidio/psicología , Cicatrización de Heridas/efectos de los fármacos
12.
J Am Assoc Nurse Pract ; 32(1): 37-44, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31369455

RESUMEN

In the United States, more than 130 people die each day from an opioid overdose. Nonopioid chronic pain management options are necessary in primary care. This educational innovation describes a new curriculum to teach future family nurse practitioner (FNP) prescribers holistic integrative interventions to decrease overprescribing of opioids for chronic pain management. The Modeling and Role Modeling theory and Kirkpatrick Evaluation Model guided the development and implementation of the curriculum innovation using a Try-It-On teaching-learning strategy, which focuses on immersion experience. The focus was to teach students to communicate effectively with patients in an effort to increase patient awareness of the pathophysiology of pain, risks of opioid use, and holistic integrative pain management options. Students learned to manage chronic pain within a holistic focus through immersion within integrative modalities, such as yoga, meditation, mindfulness, and guided imagery. Pre and post participation evaluations documented students' increased comfort level managing patients with chronic pain. Students reported they were much more likely to prescribe holistic integrative modalities after completing the Try-It-On learning modules. Holistic integrative interventions are a viable treatment option and/or adjunct treatment for chronic pain management. In conclusion, using the Try-It-On, teaching-learning strategy provided FNP students with the tools needed to prescribe nonopioid holistic integrative interventions to manage chronic pain.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Dolor Crónico/tratamiento farmacológico , Prescripciones de Medicamentos/normas , Enfermeras de Familia/tendencias , Prescripciones de Medicamentos/estadística & datos numéricos , Enfermería Holística/métodos , Humanos , Encuestas y Cuestionarios , Estados Unidos
14.
Perspect Psychiatr Care ; 55(4): 546-553, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31093993

RESUMEN

PURPOSE: This study aimed to describe lesbian, gay, bisexual, and transgender (LGBT) friendly providers' (1) smoking cessation recommendations to LGBT patients and (2) tobacco treatment practices for transgender patients. DESIGN AND METHODS: In-depth, semistructured phone interviews were conducted with 13 healthcare providers. FINDINGS: Four overarching themes emerged: (1) providing tobacco treatment services for LGBT patients; (2) barriers to LGBT smoking cessation; (3) prescribing practices for transgender individuals taking estrogen hormone therapy; (4) provider community outreach to promote LGBT smoking cessation. PRACTICE IMPLICATIONS: Holistic tobacco treatment services are needed to address LGBT-specific barriers to tobacco cessation, such as stress, identity-related factors, and inadequate healthcare access.


Asunto(s)
Actitud del Personal de Salud , Personal de Salud , Promoción de la Salud , Accesibilidad a los Servicios de Salud , Minorías Sexuales y de Género/psicología , Cese del Hábito de Fumar/métodos , Fumar/terapia , Adulto , Prescripciones de Medicamentos/normas , Humanos , Investigación Cualitativa , Fumar/tratamiento farmacológico , Estrés Psicológico/psicología
15.
Oncologist ; 24(5): 632-639, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30728276

RESUMEN

BACKGROUND: Financial relationships between physicians and the pharmaceutical industry are common, but factors that may determine whether such relationships result in physician practice changes are unknown. MATERIALS AND METHODS: We evaluated physician use of orally administered cancer drugs for four cancers: prostate (abiraterone, enzalutamide), renal cell (axitinib, everolimus, pazopanib, sorafenib, sunitinib), lung (afatinib, erlotinib), and chronic myeloid leukemia (CML; dasatinib, imatinib, nilotinib). Separate physician cohorts were defined for each cancer type by prescribing history. The primary exposure was the number of calendar years during 2013-2015 in which a physician received payments from the manufacturer of one of the studied drugs; the outcome was relative prescribing of that drug in 2015, compared with the other drugs for that cancer. We evaluated whether practice setting at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, receipt of payments for purposes other than education or research (compensation payments), maximum annual dollar value received, and institutional conflict-of-interest policies were associated with the strength of the payment-prescribing association. We used modified Poisson regression to control confounding by other physician characteristics. RESULTS: Physicians who received payments for a drug in all 3 years had increased prescribing of that drug (compared with 0 years), for renal cell (relative risk [RR] 1.81, 95% confidence interval [CI] 1.58-2.07), CML (RR 1.22, 95% CI 1.08-1.39), and lung (RR 1.69, 95% CI 1.58-1.82), but not prostate (RR 0.97, 95% CI 0.93-1.02). Physicians who received compensation payments or >$100 annually had increased prescribing compared with those who did not, but NCI setting and institutional conflict-of-interest policies were not consistently associated with the direction of prescribing change. CONCLUSION: The association between industry payments and cancer drug prescribing was greatest among physicians who received payments consistently (within each calendar year). Receipt of payments for compensation purposes, such as for consulting or travel, and higher dollar value of payments were also associated with increased prescribing. IMPLICATIONS FOR PRACTICE: Financial payments from pharmaceutical companies are common among oncologists. It is known from prior work that oncologists tend to prescribe more of the drugs made by companies that have given them money. By combining records of industry gifts with prescribing records, this study identifies the consistency of payments over time, the dollar value of payments, and payments for compensation as factors that may strengthen the association between receiving payments and increased prescribing of that company's drug.


Asunto(s)
Antineoplásicos/uso terapéutico , Industria Farmacéutica/economía , Neoplasias/tratamiento farmacológico , Oncólogos/estadística & datos numéricos , Práctica Profesional/estadística & datos numéricos , Administración Oral , Antineoplásicos/economía , Antineoplásicos/normas , Conflicto de Intereses/economía , Conjuntos de Datos como Asunto , Prescripciones de Medicamentos/economía , Prescripciones de Medicamentos/normas , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Humanos , Masculino , Oncología Médica/economía , Oncología Médica/ética , Oncología Médica/normas , Oncología Médica/estadística & datos numéricos , National Cancer Institute (U.S.)/normas , Neoplasias/economía , Oncólogos/economía , Oncólogos/ética , Práctica Profesional/economía , Práctica Profesional/ética , Práctica Profesional/normas , Estados Unidos
16.
J Gen Intern Med ; 34(8): 1419-1426, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-30684198

RESUMEN

OBJECTIVE: To determine the association of medical marijuana legalization with prescription opioid utilization. METHODS: A 10% sample of a nationally representative database of commercially insured population was used to gather information on opioid use, chronic opioid use, and high-risk opioid use for the years 2006-2014. Adults with pharmacy and medical benefits for the entire calendar year were included in the population for that year. Multilevel logistic regression analysis, controlling for patient, person-year, and state-level factors, were used to determine the impact of medical marijuana legalization on the three opioid use measures. Sub-group analysis among cancer-free adults and cancer-free adults with at least one chronic non-cancer pain condition in the particular year were conducted. Alternate regression models were used to test the robustness of our results including a fixed effects model, an alternate definition for start date for medical marijuana legalization, a person-level analysis, and a falsification test. RESULTS: The final sample included a total of 4,840,562 persons translating into 15,705,562 person years. Medical marijuana legalization was found to be associated with a lower odds of any opioid use: OR = 0.95 (0.94-0.96), chronic opioid use: OR = 0.93 (0.91-0.95), and high-risk opioid use: OR = 0.96 (0.94-0.98). The findings were similar in both the sub-group analyses and all the sensitivity analyses. The falsification tests showed no association between medical marijuana legalization and prescriptions for antihyperlipidemics (OR = 1.00; CI 0.99-1.01) or antihypertensives (OR = 1.00; CI 0.99-1.01). CONCLUSIONS: In states where marijuana is available through medical channels, a modestly lower rate of opioid and high-risk opioid prescribing was observed. Policy makers could consider medical marijuana legalization as a tool that may modestly reduce chronic and high-risk opioid use. However, further research assessing risk versus benefits of medical marijuana legalization and head to head comparisons of marijuana versus opioids for pain management is required.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Prescripciones de Medicamentos , Legislación de Medicamentos/tendencias , Marihuana Medicinal/uso terapéutico , Trastornos Relacionados con Opioides/epidemiología , Adulto , Analgésicos Opioides/efectos adversos , Dolor Crónico/tratamiento farmacológico , Dolor Crónico/epidemiología , Prescripciones de Medicamentos/normas , Femenino , Humanos , Legislación de Medicamentos/normas , Masculino , Marihuana Medicinal/efectos adversos , Persona de Mediana Edad , Trastornos Relacionados con Opioides/diagnóstico , Factores de Riesgo
17.
Can J Psychiatry ; 64(5): 351-355, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30602305

RESUMEN

OBJECTIVE: The study sought to describe a Canadian sample of university students' medicinal use of cannabis, including prevalence of cannabis use disorder (CUD) and replacement of traditional treatments with cannabis. METHOD: A random sample of 4000 university students was asked to complete a cross-sectional web-based survey. The survey was completed by 2212 (average age 23.2 years, SD = 5.2 years), representing a 55.3% response rate. To be eligible, students had to be enrolled in a class on campus and were 18 years or older. RESULT: Half (52%) of respondents used cannabis at least once in their lifetime, with ∼11% reporting medicinal cannabis use. Recreational motives to use cannabis were common among medicinal users (85%), several (38%) replaced traditional medication with cannabis, and more than a third received authorization by a health care provider. Of the medicinal users, 13.6% met the criteria for CUD. Common ailments for medicinal cannabis use were anxiety, sleep problems, depression, and pain. When mental health-related categories are combined, 78.2% of medicinal users used for at least 1 mental health condition. CONCLUSIONS: Medicinal cannabis use occurs among university students. None of the ailments listed by medicinal users meet the Canadian Family Physicians prescribing guidelines, and most are not among those viewed by the National Academies of Science, Engineering, and Medicine as having strong evidence for therapeutic value. The results raise concerns for health care providers who are authorizing or counselling patients' considering medicinal cannabis.


Asunto(s)
Prescripciones de Medicamentos/normas , Uso de la Marihuana/epidemiología , Marihuana Medicinal/uso terapéutico , Estudiantes/estadística & datos numéricos , Adolescente , Adulto , Canadá/epidemiología , Adhesión a Directriz/normas , Humanos , Universidades/estadística & datos numéricos , Adulto Joven
18.
Pharmacoepidemiol Drug Saf ; 28(1): 90-96, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30375121

RESUMEN

PURPOSE: The purpose of the study is to determine whether initiatives to improve the safety of opioid prescribing decreased injuries in people using chronic opioid therapy (COT). METHODS: We conducted an interrupted time series analysis using data from Group Health (GH), an integrated health care delivery system in the United States. In 2007, GH implemented initiatives which substantially reduced daily opioid dose and increased patient monitoring. Among GH members age 18 or older receiving COT between 2006 and 2014, we compared injury rates for patients in GH's integrated group practice (IGP; exposed to the initiatives) vs patients cared for by contracted providers (not exposed). Injuries were identified using a validated algorithm. We calculated injury incidence during the baseline (preintervention) period from 2006 to 2007; the dose reduction period, 2008 to 2010; and the risk stratification and monitoring period, 2010 to 2014. Using modified Poisson regression, we estimated adjusted relative risks (RRs) representing the relative change per year in injury rates. RESULTS: Among 21 853 people receiving COT in the IGP and 8260 in contracted care, there were 2679 injuries during follow-up. The baseline injury rate was 1.0% per calendar quarter in the IGP and 0.9% in contracted care. Risk reduction initiatives did not decrease injury rates: Within the IGP, the RR in the dose reduction period was 1.01 (95% CI, 0.95-1.07) and in the risk stratification and monitoring period, 0.99 (95% CI, 0.95-1.04). Injury trends did not differ between the two care settings. CONCLUSIONS: Risk reduction initiatives did not decrease injuries in people using COT.


Asunto(s)
Analgésicos Opioides/efectos adversos , Dolor Crónico/tratamiento farmacológico , Traumatismos Craneocerebrales/epidemiología , Prestación Integrada de Atención de Salud/normas , Pautas de la Práctica en Medicina/normas , Adulto , Anciano , Traumatismos Craneocerebrales/etiología , Prestación Integrada de Atención de Salud/organización & administración , Prescripciones de Medicamentos/normas , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Implementación de Plan de Salud , Humanos , Incidencia , Análisis de Series de Tiempo Interrumpido , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/estadística & datos numéricos , Evaluación de Programas y Proyectos de Salud , Estados Unidos
19.
Pain Med ; 20(6): 1148-1155, 2019 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-30204893

RESUMEN

OBJECTIVE: To examine the correlates and odds of receiving overlapping benzodiazepine and opioid prescriptions and whether co-prescription was associated with greater odds of falling or visiting the emergency department. DESIGN: Cross-sectional study. SETTING: A large private integrated health system and a Veterans Health Administration integrated health system. SUBJECTS: Five hundred seventeen adults with musculoskeletal pain and current prescriptions for long-term opioid therapy. METHODS: A multivariate logistic regression model examined correlates of having overlapping benzodiazepine and opioid prescriptions in the year before enrollment in the cross-sectional study. Negative binomial models analyzed the number of falls in the past three months and past-year emergency department visits. In addition to propensity score adjustment, models controlled for demographic characteristics, psychiatric diagnoses, medications, overall comorbidity score, and opioid morphine equivalent dose. RESULTS: Twenty-five percent (N = 127) of participants had co-occurring benzodiazepine and opioid prescriptions in the prior year. Odds of receiving a benzodiazepine prescription were significantly higher among patients with the following psychiatric diagnoses: anxiety disorder (adjusted odds ratio [AOR] = 4.71, 95% confidence interval [CI] = 2.67-8.32, P < 0.001), post-traumatic stress disorder (AOR = 2.24, 95% CI = 1.14-4.38, P = 0.019), and bipolar disorder (AOR = 3.82, 95% CI = 1.49-9.81, P = 0.005). Past-year overlapping benzodiazepine and opioid prescriptions were associated with adverse outcomes, including a greater number of falls (risk ratio [RR] = 3.27, 95% CI = 1.77-6.02, P = 0.001) and emergency department visits (RR = 1.66, 95% CI = 1.08-2.53, P = 0.0194). CONCLUSIONS: Among patients with chronic pain prescribed long-term opioid therapy, one-quarter of patients had co-occurring prescriptions for benzodiazepines, and dual use was associated with increased odds of falls and emergency department visits.


Asunto(s)
Analgésicos Opioides/administración & dosificación , Benzodiazepinas/administración & dosificación , Dolor Crónico/diagnóstico , Dolor Crónico/tratamiento farmacológico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Accidentes por Caídas/prevención & control , Anciano , Analgésicos Opioides/efectos adversos , Benzodiazepinas/efectos adversos , Dolor Crónico/epidemiología , Estudios Transversales , Esquema de Medicación , Prescripciones de Medicamentos/normas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad
20.
Zhongguo Zhong Yao Za Zhi ; 43(20): 4163-4168, 2018 Oct.
Artículo en Chino | MEDLINE | ID: mdl-30486545

RESUMEN

To summary and analyze the prescription rules of Professor Chen Baogui, a famous traditional Chinese medicine (TCM) doctor, for treating epigastric fullness. Professor Chen Baogui's prescriptions for treating epigastric fullness were collected and the treatment data were input into traditional Chinese medicine inheritance support system (TCMISS) to analyze the rules of the prescriptions by using data mining methods. Based on the screened 214 cases, the treatment experience of Professor Chen Baogui for treating epigastric fullness was summarized and analyzed. It was found that Professor Chen gave priority to recuperation of Qi activity. The results of four properties and five tastes showed Professor Chen's medication compatibility rules: one was simultaneous use of cold and warm drugs, and the other was simultaneous use of pungent drugs for dispersion and bitter drugs for purgation. In drug use, the basic prescriptions had the efficacy of promoting Qi circulation and regulating viscera function, additionally with the drugs with functions of eliminating digestion and inducing stagnation, activating blood circulation to dissipate blood stasis, replenishing Qi and nourishing Yin, tranquilizing mind, strengthening muscles and bones according to the TCM syndrome type. The clinical experience of Professor Chen for treating epigastric fullness was objectively summarized with the help of TCMISS, which was significant for analyzing and inheriting academic thinking and medication experience from famous TCM doctors.


Asunto(s)
Minería de Datos , Prescripciones de Medicamentos/normas , Medicamentos Herbarios Chinos/uso terapéutico , Estómago/efectos de los fármacos , Digestión/efectos de los fármacos , Humanos , Medicina Tradicional China
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA